"Norethindrone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for contraception.
| Descriptor ID |
D009640
|
| MeSH Number(s) |
D04.210.500.668.651.693.651
|
| Concept/Terms |
Norethindrone- Norethindrone
- Norpregneninolone
- Norethisterone
- Ethinylnortestosterone
|
Below are MeSH descriptors whose meaning is more general than "Norethindrone".
Below are MeSH descriptors whose meaning is more specific than "Norethindrone".
This graph shows the total number of publications written about "Norethindrone" by people in this website by year, and whether "Norethindrone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Norethindrone" by people in Profiles.
-
The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin levels: A secondary study from the WHICH randomized clinical trial. PLoS One. 2024; 19(8):e0307736.
-
Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial. PLoS One. 2024; 19(3):e0295764.
-
Misreporting contraceptive use and the association of peak study progestin levels with weight and BMI among women randomized to the progestin-only injectable contraceptives DMPA-IM and NET-EN. PLoS One. 2023; 18(12):e0295959.
-
Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels. PLoS One. 2018; 13(4):e0196043.
-
Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial. Reprod Health. 2016 Apr 18; 13:42.
-
Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk. Lancet HIV. 2015 Sep; 2(9):e365.
-
The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor. PLoS One. 2014; 9(5):e96497.
-
Differential glucocorticoid receptor-mediated effects on immunomodulatory gene expression by progestin contraceptives: implications for HIV-1 pathogenesis. Am J Reprod Immunol. 2014 Jun; 71(6):505-12.
-
Assessing menopausal status in women aged 40 - 49 using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraception. S Afr Med J. 2011 Feb; 101(2):131-5.
-
Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception. Contraception. 2010 Jan; 81(1):30-4.